Suchergebnisse - "Weinreich, David M"

PubPharm (37)

1

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

enthalten in: bioRxiv.org | 2024

von Sivapalasingam, S. | Lederer, D. | Bhore, R. | +37

2

Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims Database

enthalten in: bioRxiv.org | 2024

von Hussein, M. | Wei, W. | Mastey, V. | +6

3

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

enthalten in: Scientific reports | 2023

von Li, D. | Xu, M. | Hooper, A. | +9

4

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019 : A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial

enthalten in: Open forum infectious diseases | 2023

von Somersan-Karakaya, S. | Mylonakis, E. | Mou, J. | +14

5

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

enthalten in: bioRxiv.org | 2022

von Horby, P. | Mafham, M. | Peto, L. | +31

6

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

enthalten in: The Journal of infectious diseases | 2022

von Somersan-Karakaya, S. | Mylonakis, E. | Menon, V. | +31

7

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

enthalten in: mBio | 2022

von Hooper, A. | Somersan-Karakaya, S. | McCarthy, S. | +12

8

Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting : a retrospective cohort study using a large claims database

enthalten in: BMJ open | 2022

von Hussein, M. | Wei, W. | Mastey, V. | +6

9

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2022

von Jalbert, J. | Hussein, M. | Mastey, V. | +9

10

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Herman, G. | O'Brien, M. | Forleo-Neto, E. | +127

CommentIn: Lancet Infect Dis. 2022 Oct;22(10):1400-1401. - PMID 35803288